MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Completed · Phase 1

Conditions studied: Tumors, Neoplasm Metastasis

In brief

This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.

Key facts

Study ID

NCT00207103

Run by

Bristol-Myers Squibb

People needed

68

Starts

2004-09-01

Expected to finish

2008-09-01

Last updated by the study team

2008-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors
• No tumor spread to the brain
• Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)
• Available tumor tissue sample from prior surgery
• 4-6 weeks since prior therapy and recovered from prior therapy
• Men and women, ages 18 and above
• Women must not be pregnant or breastfeeding
• Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer
• Measurable disease on scans (at least one)

Where it is running

• Premiere Oncology — Santa Monica, California, United States
• Indiana University Med Center — Indianapolis, Indiana, United States
• University Of Wisconsin Comprehensive Center — Madison, Wisconsin, United States
• Local Institution — Edmonton, Alberta, Canada
• Local Institution — Ottawa, Ontario, Canada
• Local Institution — Milan, Italy
• Local Institution — Middlesex, Greater London, United Kingdom
• Local Institution — Manchester, Greater Manchester, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.